Scandion Oncology Q3 2024: Searching for a partner - Redeye

Redeye comments on Scandion Oncology’s Q3 2024 report, and we judge a potential partnership or similar is its best hope of advancing SCO-101’s clinical development. We judge potential partners have considerable negotiating leverage, and we lower our deal estimates to account for Scandion’s weak negotiating position. If Scandion cannot find a partner, we perceive an increasing risk of our bear case materialising.

Länk till analysen i sin helhet: https://www.redeye.se/research/1054888/scandion-oncology-q3-2024-searching-for-a-partner?utm_source=finwire&utm_medium=RSS